ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments
July 09 2024 - 5:30AM
ANEW MEDICAL, INC.
(NASDAQ: WENA) (“ANEW”), a
biopharmaceutical company specializing in the advancement of novel
disease-modifying therapies for neurological and age-related
disorders, announces plans to advance its recently patented Klotho
gene therapy program for neurodegenerative disorders.
ANEW has compelling initial data suggesting that
maintaining elevated levels of Klotho in the body significantly
contributes to longer, healthier lifespans. Conversely, the data
reveals that individuals with depleted or lower-than-normal levels
of Klotho are more susceptible to neurodegenerative disorders such
as ALS, Alzheimer’s, and Parkinson’s Disease. ANEW will also
investigate other age-related disorders associated with depleted
Klotho levels, such as memory loss, osteoporosis, sarcopenia
(muscle wasting), diabetes mellitus, and certain cardiovascular
conditions.
Dr. Joseph Sinkule, CEO and Founder of ANEW
MEDICAL, commented: “Administering a medication based on the Klotho
isoform of interest, secreted Klotho (s-KL), may contribute to
longer, healthier lives. Research by our strategic partner, the
Okinawa Research Center for Longevity Science (ORCLS) in Japan,
suggests that the Klotho gene is a key factor in age-related
longevity. Klotho emerged as one of the two most significant genes
from their studies, and we look forward to continuing our research
with ORCLS as we advance ANEW’s clinical development programs for
Neurodegenerative Disorders.”
ANEW has development plans to advance its
program in three distinct areas:
- FDA
Clinical Trials: The development of therapeutics to treat
neurodegenerative diseases and age-related disorders involves using
an adenovirus (AAV) vector to deliver the secreted Klotho gene DNA
sequence to neurons in the central nervous system (CNS). This
approach aims to correct deficiencies in the levels of s-KL.
- Klotho
Diagnostics: The development and commercialization of a
diagnostic that will enable healthcare providers to accurately
quantify levels of Klotho gene and protein isoforms in blood
samples. This tool will also provide ANEW with the necessary
diagnostic to screen patients for its clinical trials.
-
Age-Related Disorders: ANEW plans to develop
exploratory approaches to promote longevity in healthy populations
using gene or cell-based Klotho therapies, as well as other genes
of interest that are directly related to longevity.
Dr. Shalom Hirshman, M.D., Chief Medical Advisor
and Board member, stated: “ANEW is in a strong position to
significantly influence the treatment of ALS, Alzheimer’s, and
other neurodegenerative disorders. With our patent-protected gene
therapy platform technology, we have the potential to improve
health and extend life expectancy.”
About ANEW MEDICAL, INC.: ANEW
MEDICAL is a biopharmaceutical company specializing in the
advancement of novel disease-modifying therapies for neurological
and age-related disorders. The company's focus on central nervous
systems (CNS) diseases utilizing cell and gene therapies to
mitigate age-related pathologies such as Alzheimer's disease,
dementia symptoms and neuromuscular diseases. The Company has
exclusive worldwide rights to develop and commercialize proprietary
product platforms based on its proprietary isoform transcribed from
the human Klotho gene referred to as secreted Klotho or "s-KL".
This s-KL protein or gene therapy has been recognized for its
potential to mitigate age-related pathologies such as ALS,
Alzheimer's and Parkinson's Disease. The Company is also evaluating
other core technology platforms to acquire for development and
commercialization by the Company. For more information, please
visit: www.anewmeds.com.
About Klotho:Klotho is a gene
that is integral to aging and cognitive function. The gene encodes
two main protein variants: the full-length Klotho which is produced
in the kidneys to regulate phosphate and calcium, and the secreted
Klotho (s-KL) which is an RNA splice variant primarily synthesized
in the brain. The s-KL variant is essential for maintaining normal
brain and neurological functions. ANEW’s gene therapy program
targeting klotho shows significant potential in treating
age-related diseases like Amyotrophic Lateral Sclerosis (ALS),
Alzheimer's Disease, and Parkinson's Disease. ANEW’s s-KL programs
are advancing the use of Klotho as a target for gene and cell
therapies, as well as in diagnostics for neurological and
age-related disorders.
Forward-Looking Statements:This
press release contains forward-looking statements. These statements
are made under the “safe harbor” provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements generally are identified by the words “believe,”
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions. Without limiting the generality of the
foregoing, the forward-looking statements in this press release
include descriptions of the Company’s future commercial operations.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, such as the Company’s inability to implement its business
plans, identify and realize additional opportunities, or meet or
exceed its financial projections and changes in the regulatory or
competitive environment in which the Company operates. You should
carefully consider the foregoing factors and the other risks and
uncertainties described in the documents filed or to be filed by
the Company with the U.S. Securities and Exchange Commission (the
“SEC”) from time to time, which could cause actual events and
results to differ materially from those contained in the
forward-looking statements. Copies of these documents are available
on the SEC’s website, www.sec.gov. All information provided
herein is as of the date of this press release, and the Company
undertakes no obligation to update any forward-looking statement,
except as required under applicable law.
For more information, contact:Investor
Relations and Public RelationsEric Boyd eric@anewmeds.comorPCG
Advisory LLC. Jeff Ramson or Adam Holdsworth
Email: ir@anewmeds.comWebsite: www.anewmeds.com
ANEW MEDICAL (NASDAQ:WENA)
Historical Stock Chart
From Aug 2024 to Sep 2024
ANEW MEDICAL (NASDAQ:WENA)
Historical Stock Chart
From Sep 2023 to Sep 2024